Physician profile
Marguerite A Butchee
NPI 1558622282
$323,562.61
in general payments reported to CMS, 2019-2025
73 companies · $74K in 2025
The $74K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,327 · 2020: $8,896 · 2021: $83K · 2022: $62K · 2023: $42K · 2024: $45K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $124K · Travel and Lodging: $16K · Food and Beverage: $15K · Consulting Fee: $5,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $123,881.25 |
| Travel and Lodging | $16,180.05 |
| Food and Beverage | $15,282.27 |
| Consulting Fee | $5,725.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $161,389.08 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $51,129.64 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $28,535.21 | 2021 | |
| Allergan, INC. | $19,889.45 | 2019-2022 | |
| Lilly USA, LLC | $17,826.90 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Amgen INC. | $14,776.53 | 2019-2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company Ltd. | $10,471.18 | 2022 | |
| Impel Pharmaceuticals INC. | $1,956.62 | 2022-2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $1,728.55 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Ucb, INC. | $1,308.34 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Lundbeck LLC | $1,307.00 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $1,067.60 | 2019-2025 | |
| Sk Life Science, INC. | $899.29 | 2020-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $891.90 | 2020-2025 | Nuplazid, Daybue |
| Alexion Pharmaceuticals, INC. | $662.17 | 2019-2025 | Ultomiris |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $642.03 | 2019-2021 | |
| Genzyme Corporation | $622.57 | 2019-2023 | |
| Livanova USA, INC. | $563.23 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $557.85 | 2019-2025 | Vumerity, Tysabri |
| Merz Pharmaceuticals, LLC | $539.55 | 2021-2025 | Xeomin, Inbrija |
| Amneal Pharmaceuticals LLC | $531.56 | 2019-2025 | Rytary, Ongentys, Crexont |
| Eisai INC. | $526.01 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $471.82 | 2021-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $447.47 | 2024-2025 | |
| Csl Behring | $377.73 | 2020-2025 | Hizentra |
| Sunovion Pharmaceuticals INC. | $373.21 | 2019-2022 | |
| Genentech USA, INC. | $345.28 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Grifols USA, LLC | $264.33 | 2019-2025 | Gamunex-C |
| Argenx US, INC. | $253.27 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Upsher-Smith Laboratories LLC | $211.37 | 2019-2022 | |
| Mdd US Operations, LLC | $208.58 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $196.55 | 2020-2024 | Onpattro |
| Sumitomo Pharma America, INC. | $178.88 | 2023-2024 | Aptiom |
| Acorda Therapeutics, INC | $160.22 | 2019-2023 | Inbrija, Ampyra |
| Banner Life Sciences, LLC | $148.16 | 2023 | |
| Ge Healthcare | $146.98 | 2021-2025 | |
| Medtronic USA, INC. | $132.42 | 2019 | |
| Emd Serono, INC. | $118.02 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.56 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $93.85 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $89.32 | 2022-2025 | |
| Greenwich Biosciences, INC. | $86.32 | 2019 | |
| Celgene Corporation | $85.85 | 2021 | |
| Adamas Pharmaceuticals, INC. | $81.77 | 2019-2021 | |
| Corium, LLC | $76.25 | 2022-2023 | Adlarity |
| Mallinckrodt Enterprises LLC | $73.17 | 2019 | |
| Kyowa Kirin, INC. | $71.18 | 2021 | |
| Horizon Therapeutics Plc | $61.57 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $61.39 | 2023-2024 | Firdapse, Fycompa |
| Avanir Pharmaceuticals, INC. | $60.62 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $58.08 | 2019-2020 | |
| Merz North America, INC. | $52.84 | 2019 | |
| Tanabe Pharma America, INC. | $48.14 | 2019-2022 | |
| Promius Pharma LLC | $47.03 | 2019 | |
| Medtronic, INC. | $46.30 | 2022-2025 | Inceptiv, Intellis Adaptivestim |
| Impel Pharmaceuticals LLC | $45.53 | 2024-2025 | Trudhesa |
| Ani Pharmaceuticals, INC. | $40.83 | 2022-2025 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $39.58 | 2021-2022 | |
| Axsome Therapeutics, INC. | $37.49 | 2025 | Symbravo |
| Avion Pharmaceuticals | $34.46 | 2022-2023 | Dhivy |
| Azurity Pharmaceuticals, INC. | $32.23 | 2023-2024 | Horizant, Horizant |
| Ipsen Biopharmaceuticals, INC | $28.85 | 2025 | Dysport |
| Scilex Pharmaceuticals INC. | $28.72 | 2023-2024 | Ztlido |
| Vanda Pharmaceuticals INC. | $28.13 | 2025 | Ponvory |
| Vertical Pharmaceuticals, LLC | $27.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.57 | 2024 | Hyqvia |
| Ns Pharma, INC. | $24.20 | 2023 | Viltepso |
| Collegium Pharmaceutical, INC. | $23.27 | 2022 | |
| Sandoz INC. | $23.12 | 2023 | |
| Dynasplint Systems INC. | $20.27 | 2025 | Dynasplint |
| Neurelis, INC. | $16.94 | 2023 | Valtoco |
| Currax Pharmaceuticals LLC | $12.89 | 2023 | Onzetra Xsail |
| Zyla Life Sciences, INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marguerite Butchee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.